Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

Eli Lilly and Novo Nordisk , the two pharmas dominating the weight loss drugs market, surged Thursday morning after the US ...

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...

By Chris Prentice and Mariam Sunny April 29 (Reuters) - Eli Lilly investors will be searching for something they won't find ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding ...

Novo Nordisk (NYSE:NVO) is advancing the launch of an oral version of Ozempic, expanding its GLP-1 diabetes franchise beyond injectable formats. The company is also seeking regulatory approvals to ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

Eli Lilly (LLY) stock jumps as the company raised its full-year outlook alongside better-than-expected Q1 2026 financials ...

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Eli Lilly (LLY 2.56%) has established itself as the leader in the weight-loss drug market. Since this area is projected to ...